Shots:
- Pfizer will continue to provide sales and marketing support and health system support for Cologuard through the end of 2022 and 2021, respectively. Exact Sciences will compensate Pfizer based on the amount of services provided, along with additional fixed and performance-related fees set forth in the agreement
- Cologuard was approved by US FDA in August 2014 and is included in American Cancer Society’s (2018) colorectal cancer screening guidelines. It is indicated to screen adults (aged 45 yrs. and older) who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool
- Cologuard is the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. It is an accurate, at-home colon cancer screening option and is uniquely positioned to support screening during this time and after the pandemic abates
Click here to read full press release/ article | Ref: PR Newswire | Image: WMTV
The post Exact Sciences and Pfizer Announce Extension and Amendment of their Cologuard Promotion Agreement first appeared on PharmaShots.
